Author

A. J. Gill

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. A. Hakimi· 1 shared A. C. Vargas· 1 shared A. Guo· 1 shared A. Johns· 1 shared A. L. Cheah· 1 shared A. M. Carter· 1 shared A. Mahar· 1 shared A. Mawson· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 8 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Hakimi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer

J. Kokkinos, G. Sharbeen, R. M. C. Ignacio, E. Pandzic, J. Youkhana, C. Boyer, K. S. Haghighi, M. Gunawarman, D. Goldstein, V. Gebski, M. Pajic, O. Pitiyarachchi, M. E. Davis, G. Schulstad, O. S. M. Arkell, , P. A. Phillips

This study identifies βIII-tubulin as a suppressor of extrinsic apoptosis in pancreatic cancer, showing that its silencing enhances sensitivity to death signals and reduces tumor progression.

bioRxiv · Sep 29, 2022 · PreprintCancer Biology

Genomic and Metabolic Hallmarks of SDH- and FH-Deficient Renal Cell Carcinomas

A. Yoo, C. Tang, M. Zucker, K. Fitzgerald, P. M. Rappold, K. Weiss, B. Freeman, C.-H. Lee, N. Schultz, R. Motzer, P. Russo, J. Coleman, V. E. Reuter, Y.-B. Chen, M. I. Carlo, , E. Reznik

This study compares the genomic and metabolic features of SDH- and FH-deficient renal cell carcinomas, identifying distinct genetic and metabolic abnormalities.

bioRxiv · Jun 9, 2021Cancer Biology

PD-L1 expression in 522 selected sarcomas with subset analysis of recurrent or metastatic matched samples and association with tumour-infiltrating lymphocytes

A. C. Vargas, F. M. Maclean, L. Sioson, D. Tran, F. Bonar, A. Mahar, A. L. Cheah, P. Russell, P. G. Peter Grimison, L. R. Louise Richardson, A. J. Gill

This study evaluates PD-L1 expression in 522 sarcomas, finding variability across subtypes and demonstrating increased PD-L1 in some metastatic/recurrent samples, suggesting potential for immune checkpoint inhibitor therapy.

bioRxiv · Sep 4, 2019Cancer Biology

Phosphoprotein-based Biomarkers as Predictors for Cancer Therapy

A. M. Carter, C. Tan, K. Pozo, R. Telange, R. Molinaro, A. Guo, E. De Rosa, J. O. Martinez, S. Zhang, N. Kumar, M. Takahashi, T. Wiederhold, H. K. Ghayee, S. C. Oltmann, K. Pacak, , J. A. Bibb

The paper identifies phosphoprotein biomarkers for Cdk5 activity in neuroendocrine tumors and shows their predictive value for anti-Cdk5 therapy.

bioRxiv · Jun 20, 2019Cancer Biology